Published in Am J Physiol Heart Circ Physiol on March 16, 2007
The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue. Heart Vessels (2014) 0.92
Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart. Br J Pharmacol (2015) 0.85
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol (2014) 0.84
Uncx regulates proliferation of neural progenitor cells and neuronal survival in the olfactory epithelium. Mol Cell Neurosci (2010) 0.83
Morphine Reduces Myocardial Infarct Size via Heat Shock Protein 90 in Rodents. Biomed Res Int (2015) 0.78
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther (2011) 0.76
Delta-opioid augments cardiac contraction through β-adrenergic and CGRP-receptor co-signaling. Peptides (2011) 0.76
Activation of beta-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists. Med Res Rev (2016) 0.75
Universal definition of myocardial infarction. Circulation (2007) 11.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Reversal of ischemia of donor artery myocardium after recanalization of a chronic total occlusion. Catheter Cardiovasc Interv (2013) 2.71
2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2014) 2.58
Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet (2011) 2.48
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Video-rate nanoscopy using sCMOS camera-specific single-molecule localization algorithms. Nat Methods (2013) 2.28
Pseudoaneurysm of the mitral-aortic intervalvular fibrosa (MAIVF): A comprehensive review. J Am Soc Echocardiogr (2010) 2.24
The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. J Am Coll Cardiol (2012) 2.13
Cost of Gram-negative resistance. Crit Care Med (2007) 2.05
Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation (2006) 2.00
Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction. J Electrocardiol (2006) 1.84
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res (2005) 1.78
Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv (2002) 1.62
Contact isolation in surgical patients: a barrier to care? Surgery (2003) 1.60
Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther (2006) 1.58
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther (2007) 1.56
Inhibition of IL-6 signaling: A novel therapeutic approach to treating spinal cord injury pain. Pain (2013) 1.56
Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation (2003) 1.55
The effect of CTO recanalization on FFR of the donor artery. Catheter Cardiovasc Interv (2011) 1.54
The current status and future direction of percutaneous coronary intervention without on-site surgical backup: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2007) 1.53
The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics (2010) 1.48
Treatment of the chronic total occlusion: a call to action for the interventional community. Catheter Cardiovasc Interv (2014) 1.46
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther (2012) 1.45
The myocardium supplied by a chronic total occlusion is a persistently ischemic zone. Catheter Cardiovasc Interv (2013) 1.45
Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Electrocardiol (2011) 1.45
Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheter Cardiovasc Interv (2008) 1.44
The 3rd DBCLS BioHackathon: improving life science data integration with Semantic Web technologies. J Biomed Semantics (2013) 1.44
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther (2014) 1.43
Pyelonephritic Escherichia coli expressing P fimbriae decrease immune response of the mouse kidney. J Am Soc Nephrol (2005) 1.43
Quality assessment and improvement in interventional cardiology: a Position Statement of the Society of Cardiovascular Angiography and Interventions, Part II: public reporting and risk adjustment. Catheter Cardiovasc Interv (2011) 1.42
Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol (2007) 1.42
Prolonged high-pressure is required for optimal stent deployment as assessed by optical coherence tomography. Catheter Cardiovasc Interv (2013) 1.42
Cardiac arrest on induction of anesthesia due to triple vessel coronary artery disease despite a "Negative" angiogram. Anesthesiology (2002) 1.40
Symptomatic right ventricular ischemia secondary to a critical stenosis in a nondominant right coronary artery. Catheter Cardiovasc Interv (2012) 1.40
Treatment of chronic total occlusion by retrograde passage of stents through an epicardial collateral vessel. Catheter Cardiovasc Interv (2008) 1.40
Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction. J Electrocardiol (2006) 1.39
Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? Catheter Cardiovasc Interv (2008) 1.39
Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res (2007) 1.39
Retrograde fractional flow reserve and recanalization of a chronic total occlusion of a saphenous venous graft. Catheter Cardiovasc Interv (2012) 1.39
Left atrial inflow and outflow obstruction as a complication of retrograde approach for chronic total occlusion: report of a case and literature review of left atrial hematoma after percutaneous coronary intervention. Catheter Cardiovasc Interv (2013) 1.38
High-frequency QRS electrocardiogram predicts perfusion defects during myocardial perfusion imaging. J Electrocardiol (2005) 1.37
Pacing on the T Wave: What Is the Cause? Tex Heart Inst J (2016) 1.37
Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injury. Exp Neurol (2006) 1.34
Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res (2010) 1.33
An intradermal environment promotes a protective type-1 response against lethal systemic monocytotropic ehrlichial infection. Infect Immun (2006) 1.31
Transcriptional profiling of spinal cord injury-induced central neuropathic pain. J Neurochem (2005) 1.31
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res (2006) 1.30
Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol (2005) 1.28
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol (2010) 1.24
Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. Autophagy (2015) 1.24
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol (2005) 1.23
Simultaneous measurement of deep tissue blood flow and oxygenation using noncontact diffuse correlation spectroscopy flow-oximeter. Sci Rep (2013) 1.20
Novel cardiac apoptotic pathway: the dephosphorylation of apoptosis repressor with caspase recruitment domain by calcineurin. Circulation (2008) 1.19
Transplantation of primed human fetal neural stem cells improves cognitive function in rats after traumatic brain injury. Exp Neurol (2006) 1.18
The hamster as an animal model for eastern equine encephalitis--and its use in studies of virus entrance into the brain. J Infect Dis (2004) 1.16
Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol Heart Circ Physiol (2010) 1.15
Human fetal neural stem cells grafted into contusion-injured rat spinal cords improve behavior. J Neurosci Res (2007) 1.14
Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv (2007) 1.14
Evidence for a ferryl intermediate in a heme-based dioxygenase. Proc Natl Acad Sci U S A (2009) 1.13
Effects of pooling mRNA in microarray class comparisons. Bioinformatics (2004) 1.10
Concentrations of glutamate released following spinal cord injury kill oligodendrocytes in the spinal cord. Exp Neurol (2004) 1.08
Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment. J Pharmacol Exp Ther (2003) 1.08
Left main coronary artery thrombus: a case series with different outcomes. J Thromb Thrombolysis (2005) 1.06
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain (2013) 1.06
Trypanosoma cruzi infection disturbs mitochondrial membrane potential and ROS production rate in cardiomyocytes. Free Radic Biol Med (2009) 1.06
Ventricular free wall rupture following acute myocardial infarction. Coron Artery Dis (2003) 1.05
Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase. J Am Chem Soc (2009) 1.03
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol (2008) 1.03
Differentiating ST elevation myocardial infarction and nonischemic causes of ST elevation by analyzing the presenting electrocardiogram. Am J Cardiol (2008) 1.02
The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol (2004) 1.02
Protein adducts of malondialdehyde and 4-hydroxynonenal in livers of iron loaded rats: quantitation and localization. Toxicology (2002) 1.02
Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol (2007) 1.01
Updates on the web-based VIOLIN vaccine database and analysis system. Nucleic Acids Res (2013) 1.01
Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner. Eur J Pharmacol (2008) 1.01